By Justin Petrone

Though more and more academic centers and genetic testing firms have introduced microarray-based screening for constitutional abnormalities in recent years, the offerings are not accessible enough to the pediatricians who are most in need of the test, according to Michael Paul, CEO of Salt Lake City-based Lineagen.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.